Our website is made possible by displaying non-intrusive online advertisements to our visitors.
Please consider supporting us by disabling or pausing your ad blocker.
TauRx Pharmaceuticals (Not Listed) will present the 24-month data from its Phase 3 LUCIDITY trial of hydromethylthionine mesylate (HMTM) at the upcoming AD/PD 2024 Alzheimer’s & Parkinson’s Diseases Conference on 7 Mar 2024 at 13:50 Central European Time (20:50 Malaysian time), in Lisbon, Portugal. TauRx had reported initial results of its Phase III LUCIDITY trial throughout 2022 but the upcoming presentation will include details of the final 12-month open label phase of the trial.
